DanCann Pharma A/S

NGM:DANCAN Stock Report

Market Cap: DKK 8.6m

DanCann Pharma Valuation

Is DANCAN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DANCAN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate DANCAN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate DANCAN's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DANCAN?

Key metric: As DANCAN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for DANCAN. This is calculated by dividing DANCAN's market cap by their current revenue.
What is DANCAN's PS Ratio?
PS Ratio1x
SalesDKK 8.22m
Market CapDKK 8.63m

Price to Sales Ratio vs Peers

How does DANCAN's PS Ratio compare to its peers?

The above table shows the PS ratio for DANCAN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average12.6x
PHARM Pharmiva
2.3xn/aSEK 9.7m
EEVIA Eevia Health Oyj
0.7xn/aSEK 16.0m
DBP B Double Bond Pharmaceutical International
33.5xn/aSEK 40.2m
ACUC AcuCort
14xn/aSEK 97.7m
DANCAN DanCann Pharma
1xn/aDKK 8.6m

Price-To-Sales vs Peers: DANCAN is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (16x).

Price to Sales Ratio vs Industry

How does DANCAN's PS Ratio compare vs other companies in the SE Pharmaceuticals Industry?

10 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.15.7x32.9%
DANCAN DanCann Pharma
 1xn/aUS$1.21m
SECARE Swedencare
2.9x12.0%US$647.75m
ORX Orexo
0.5x11.3%US$29.26m
DANCAN 1.0xIndustry Avg. 15.7xNo. of Companies10PS01224364860+
10 CompaniesEstimated GrowthMarket Cap
Industry Avg.15.7x75.8%
DANCAN DanCann Pharma
 1xn/aUS$1.21m
No more companies

Price-To-Sales vs Industry: DANCAN is good value based on its Price-To-Sales Ratio (1x) compared to the Swedish Pharmaceuticals industry average (16.3x).

Price to Sales Ratio vs Fair Ratio

What is DANCAN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DANCAN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate DANCAN's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

AstraZeneca

UK£156.0b

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AZN

UK£1,413.50

7D

-1.8%

1Y

4.5%

Swedish Orphan Biovitrum

SEK 99.8b

An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

SOBI

SEK 290.60

7D

-12.4%

1Y

15.7%

PMD Device Solutions

SEK 33.2m

A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.

PMDS

SEK 1.28

7D

-14.7%

1Y

n/a